# DETERMINATION AND COMPARISON OF PERSISTENT ORGANOCHLORINE COMPOUNDS IN SOIL REFERENCE MATERIALS 

Joseph Palausky ${ }^{1}$, Mark Davis, Anne-Marie Owens, Steven Baca ${ }^{2}$, and Gerry Henningsen ${ }^{3}$<br>'Midwest Research Institute, 425 Volker Blvd., Kansas City, MO 64110<br>${ }^{2}$ URS Greiner Woodward Clyde Federal Services, Denver, CO 80022<br>${ }^{3}$ U.S. EPA 8EPR-PS, $99918^{\text {th }}$ St., Suite 500, Denver, CO 80202

## Introduction

Approximately 250 soil samples have been submitted for analysis to investigate the levels of polychlorinated dibenzo- $p$-dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs), co-planar polychlorinated biphenyls (Co-PCBs) and mono-ortho polychlorinated biphenyls (MO-PCBs) in urban soils. With each process batch of samples, additional quality control (QC) or reference soil samples have been submitted to monitor ongoing precision and accuracy. The reference soil samples have been used historically on a large number of studies but have only been classified for PCDD/PCDF concentration. These reference soils, however, have not previously been classified for either Co-PCBs or MO-PCBs. This paper will present the relative levels of the PCDDs/PCDFs and PCBs found in the reference soils.

## Materials and Methods

Soil samples were collected, seived to $250-\mu \mathrm{m}$ and delivered to the laboratory. All samples were prepared and analyzed according to isotope dilution quantitation specified in a method based on the techniques presented in US EPA Method $8290^{1}, 1613 \mathrm{~B}^{2}$, and Method $1668^{3}$.

Approximately $20-\mathrm{g}$ of each sample is fortified with a mixture of ${ }^{13} \mathrm{C}$-labeled PCDD/PCDF/PCB internal quantitation standards (IQS), extracted by soxhlet for 16 hours with toluene, and then concentrated. Each extract is then spiked with a cleanup standard ( ${ }^{37} \mathrm{Cl}_{4}-2,3,7,8,-\mathrm{TCDD}$ ) to monitor efficiency through the remainder of extract cleanup. The extracts are then processed through a concentrated acid shake and silica cleanup. Following silica, each extract is split with one portion reserved for PCDD/PCDF/Co-PCB analysis and the other for MO-PCB analysis. The MO-PCB extracts are fortified with ${ }^{13} \mathrm{C}$-labeled recovery standards and concentrated to a final volume of $20-\mu \mathrm{L}$ in tridecane. The PCDD/PCDF/Co-PCB extracts are further processed through alumina and carbon columns, fortified with ${ }^{13} \mathrm{C}$-labeled recovery standards and concentrated to a final volume of $10-\mu \mathrm{L}$ in tridecane.

All HRGC/HRMS analyses are conducted using a Hewlett-Packard 5890 gas chromatograph interfaced to a VG-70S-250 double focusing/dual sector high resolution mass spectrometer. A DB- 5 ms gas chromatography column ( 60 meter, 0.25 mm ID, $0.25 \mu \mathrm{~m}$ film thickness) is used. Mass spectrometer acquisition is performed at 10,000 resolution in the selected ion monitoring mode (SIM) and sensitivity of $10: 1$ signal-to-noise is routinely achieved for all calibration standards.

## ANALYSIS -POSTERS

For extract analysis, all qualitatively identified peaks above the level of 2.5 :1 signal-to-noise are quantified using isotope dilution. A six-point initial calibration curve (I-CAL) for PCDD/PCDF is performed using a $0.25-200 \mathrm{pg} / \mu \mathrm{L}$ range for tetra-substituted isomers, $1.25-1000 \mathrm{pg} / \mu \mathrm{L}$ range for penta- through hepta-substituted isomers and $2.5-2000 \mathrm{pg} / \mu \mathrm{L}$ range for octa-substituted isomers. The Co-PCB and MO-PCB I-CAL is also a six-point curve using a $2.5-500 \mathrm{pg} / \mu \mathrm{L}$ range for all isomers.

For toxic equivalency quotient (TEQ) calculations, concentrations detected in samples are multiplied by the corresponding toxic equivalency factor (TEF) presented in Table 1. For analytes that are not detected, including interference values (e.g., polychlorinated diphenyl ethers), a value of one-half the reporting limit is used for the TEQ calculation.

## Results and Discussion

A comparison of concentrations (expressed in $\mathrm{pg} / \mathrm{g}$ ) and Total TEQ is presented in Table 2. This table also breaks out the contribution for PCDD/PCDF and for PCBs separately. Results compare well between the known PCDD/PCDF TEQ and the determined PCDD/PCDF TEQ for all reference soils. The general trend is that PCBs (specifically MO-PCBS) are found at higher concentrations than are the PCDDs/PCDFs in the same sample. Based on the TEFs used, however, the percent contribution to the total TEQ from PCBs can be significant but is usually lower than the PCDD/PCDF contribution percentage.

This information is significant because it is demonstrated that PCBs be measured in the same extract with PCDDs/PCDFs and they can also cause interference and reporting of false positive results. For example, there are hexa-PCB congeners that elute within the quantitation window of the penta-CDDs. If these are not removed during sample cleanup, they may be identified as PentaCDDs (which have a higher TEF value) and cause an elevation of the Total TEQ. This can be mitigated instrumentally by monitoring of additional (different) mass ions than those specified in the standard methodologies.

## Acknowledgements

The author would like to acknowledge the assistance of Dr. Gerry Henningsen (USEPA Region 8) and Mr. Steven Baca (URS Greiner Woodward Clyde Federal Services) for continuing support.

## References

1. USEPA Method 1613, "Tetra- through Octa-Chlorinated Dioxins and Furans by Isotope Dilution HRGC/HRMS, Revision B." Oct. 1994.
2. USEPA Method 8290, "Polychlorinated Dibenzodioxins (PCDDs) and Polychlorinated Dibenzofurans (PCDFs) by High-Resolution Gas Chromatography / High Resolution Mass Spectrometry (HRGC/HRMS), Revision 0." September 1994.
3. Draft Method 1668 for the Measurement of Toxic PCB Congeners by Isotope Dilution High Resolution Gas Chromatography/High Resolution Mass Spectrometry. Draft Revision. March, 1997.
4. Van den Berg et al., Toxic Equivalency Factors (TEFs) for PCBs, PCDDs, PCDFs for Humans and Wildlife, Environmental Health Perspectives 106:775-792, 1998.

Table 1 Analytes Measured and Toxic Equivalency Factors Used

| Compound | TEF |
| :---: | :---: |
| PCDDs and PCDFs | QATS-TEF ${ }^{\text {1 }}$ |
| 2,3,7,8-TCDF | 0.1 |
| 2,3,7,8-TCDD | 1 |
| 1,2,3,7,8-PeCDF | 0.05 |
| 2,3,4,7,8-PeCDF | 0.5 |
| 1,2,3,7,8-PeCDD | 0.5 |
| 1,2,3,4,7,8-HxCDF | 0.1 |
| 1,2,3,6,7,8-HxCDF | 0.1 |
| 1,2,3,7,8,9-HxCDF | 0.1 |
| 2,3,4,6,7,8-HxCDF | 0.1 |
| 1,2,3,4,7,8-HxCDD | 0.1 |
| 1,2,3,6,7,8-HxCDD | 0.1 |
| 1,2,3,7,8,9-HxCDD | 0.1 |
| 1,2,3,4,6,7,8-HpCDF | 0.01 |
| 1,2,3,4,7,8,9-HpCDF | 0.01 |
| 1,2,3,4,6,7,8-HpCDD | 0.01 |
| OCDF | 0.001 |
| OCDD | 0.001 |
| Coplanar PCBs | 1-TEF ${ }^{2}$ |
| 3,3',4,4'-TCB (PCB 77) | 0.0001 |
| 3,4,4',5-TCB (PCB 81) | 0.0001 |
| 3,3, 4, 4, 5-PeCB (PCB 126) | 0.1 |
| 3,3',4,4',5,5'-HxCB (PCB 169) | 0.01 |
| Mono- Ortho-PCBs | I-TEF ${ }^{2}$ |
| 2,3,3',4,4'-PeCB (PCB 105) | 0.0001 |
| 2,3,4,4',5-PeCB (PCB 114) | 0.0005 |
| 2,3', 4, ${ }^{\prime}$, 5-PeCB (PCB 118) | 0.0001 |
| 2, 3, 4, ${ }^{\prime}$, 5-PeCB (PCB 123) | 0.0001 |
| 2,3,3',4,4',5-HxCB (PCB 156) | 0.0005 |
| 2,3,3',4,4',5'-HxCB (PCB 157) | 0.0005 |
| 2,3',4,4',5,5'-HxCB (PCB 167) | 0.00001 |
| 2,3, ${ }^{\prime}, 4,4^{\prime}, 5,5^{\prime}-\mathrm{HpCB}$ (PCB 189) | 0.0001 |
| USEPA QATS TEFs used for D/Fs |  |

Table 2 Concentration and TEQ Comparison Results

| Sample | Description | $\begin{gathered} \text { Known } \\ \text { D/F TEQ } \end{gathered}$ | Concentration (pg/g) |  |  | TEQ (pg/g) ${ }^{1}$ |  |  | \% of Total Concentration |  | $\begin{aligned} & \text { \% of Total } \\ & \text { TEQ } \end{aligned}$ |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | D/F | PCB |  | D/F | PCB | Total | D/F | PCB | D/F | PCB |
| 1001 |  |  | 337 | 3410 | 3750 | 4.23 | 8.76 | 13.0 | 9 | 91 | 33 | 67 |
| 1002 |  |  | 1090 | 38900 | 40000 | 94.2 | 29.7 | 124 | 3 | 97 | 76 | 24 |
| 1003 |  |  | 204 | 1160 | 1360 | 4.32 | 2.59 | 6.92 | 15 | 85 | 62 | 37 |
| 1004 | PEL-R | 35.5 | 535 | 1680 | 2210 | 35.2 | 1.22 | 36.4 | 24 | 76 | 97 | 3 |
| 1005 | CIL-R | $<5$ | 844 | 194 | 1040 | 4.59 | 1.41 | 6.00 | 81 | 19 | 77 | 24 |
| 1006 |  |  | 841 | 2110 | 2950 | 56.0 | 1.73 | 57.7 | 29 | 72 | 97 | 3 |
| 1007 |  |  | 289 | 28700 | 29000 | 30.6 | 69.7 | 100 | 1 | 99 | 31 | 70 |
| 1008 |  |  | 877 | 2260 | 3140 | 56.5 | 5.24 | 61.8 | 28 | 72 | 91 | 8 |
| 1009 |  |  | 688 | 1800 | 2480 | 49.5 | 4.72 | 54.2 | 28 | 73 | 91 | 9 |
| 1010 |  |  | 318 | 449 | 767 | 4.59 | 1.69 | 6.28 | 41 | 59 | 73 | 27 |
| 1011 | RMA-S | Blank | 20.6 | 82.7 | 103 | 1.59 | 0.599 | 2.19 | 20 | 80 | 73 | 27 |
| 1012 |  |  | 333 | 1380 | 1710 | 26.0 | 5.04 | 31.0 | 19 | 81 | 84 | 16 |
| 1013 | RMA-F | Blank | 22.9 | 90.1 | 113 | 2.32 | 0.434 | 2.75 | 20 | 80 | 84 | 16 |
| 1014 |  |  | 414 | 22500 | 22900 | 45.6 | 16.8 | 62.3 | 2 | 98 | 73 | 27 |
| 1015 |  |  | 115 | 329 | 445 | 2.80 | 1.51 | 4.30 | 26 | 74 | 65 | 35 |
| 1016 | PEM-R | 59.1 | 520 | 26200 | 26700 | 60.9 | 19.3 | 80.2 | 2 | 98 | 76 | 24 |
| 1017 |  |  | 891 | 35600 | 36500 | 96.1 | 117 | 214 | 2 | 98 | 45 | 55 |
| 1018 | RMA-B | Blank | 19.4 | 82.6 | 102 | 2.09 | 0.792 | 2.89 | 19 | 81 | 72 | 27 |

${ }^{1}$ QATS TEFs used for D/Fs and World Health Organization (Van den Berg et al., 19984) used for PCBs.

